Elicio Therapeutics, Inc. (ELTX)
- Previous Close
8.41 - Open
8.51 - Bid 7.86 x 100
- Ask 8.19 x 100
- Day's Range
7.90 - 8.58 - 52 Week Range
2.96 - 24.39 - Volume
25,177 - Avg. Volume
61,981 - Market Cap (intraday)
82.676M - Beta (5Y Monthly) --
- PE Ratio (TTM)
-- - EPS (TTM)
-3.82 - Earnings Date Aug 9, 2024 - Aug 13, 2024
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
10.00
Elicio Therapeutics, Inc., a clinical-stage biotechnology company, develops a pipeline of novel immunotherapies for the treatment of cancer. Its lead product candidate is ELI-002, a multivalent lymph nodetargeted AMP peptide vaccine that is in Phase II clinical trial to target seven Kirsten rat sarcoma viral oncogene homolog driver mutations. The company is also developing ELI-007, a multivalent lymph nodetargeted AMP peptide vaccine to target mutant v-raf murine sarcoma viral oncogene homolog B1 gene mutations found in solid tumors; and ELI-008, a multivalent lymph nodetargeted AMP peptide vaccine to target p53 hotspot mutations. The company is headquartered in Boston, Massachusetts.
elicio.comRecent News: ELTX
Performance Overview: ELTX
Trailing total returns as of 5/28/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: ELTX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: ELTX
Valuation Measures
Market Cap
86.37M
Enterprise Value
81.19M
Trailing P/E
--
Forward P/E
--
PEG Ratio (5yr expected)
--
Price/Sales (ttm)
--
Price/Book (mrq)
17.74
Enterprise Value/Revenue
--
Enterprise Value/EBITDA
--
Financial Highlights
Profitability and Income Statement
Profit Margin
0.00%
Return on Assets (ttm)
-98.95%
Return on Equity (ttm)
-1,288.17%
Revenue (ttm)
--
Net Income Avi to Common (ttm)
-38.99M
Diluted EPS (ttm)
-3.82
Balance Sheet and Cash Flow
Total Cash (mrq)
11.85M
Total Debt/Equity (mrq)
280.47%
Levered Free Cash Flow (ttm)
--